News & Updates

Stinging, burning sensation after DED medication use a major concern to patients

27 Jun 2022 by

Patients with dry eye disease (DED) can achieve optimal symptom alleviation with available medications, but getting patients to take their medications remains a challenge due to side effects. Taking the burn or sting out of medications might help, according to a Singapore study.

Stinging, burning sensation after DED medication use a major concern to patients

27 Jun 2022

Vonoprazan superior to PPI for heartburn resolution in erosive esophagitis patients

27 Jun 2022 by

Vonoprazan 20 mg once daily (QD) appears as effective as proton pump inhibitors (PPIs) on day 1 and equally or more effective on day 7 in the treatment of heartburn in adults with erosive esophagitis, results of a network meta-analysis have shown.

Vonoprazan superior to PPI for heartburn resolution in erosive esophagitis patients

27 Jun 2022

Pharmacist intervention confers benefits on cardiovascular outcomes

27 Jun 2022

Pharmacist interventions help improve cardiovascular disease management, including risk factor control, better medication adherence, and reduction in morbidity and mortality, a study has found.

Pharmacist intervention confers benefits on cardiovascular outcomes

27 Jun 2022

Infliximab, adalimumab biosimilars effective, safe in paediatric IBD

27 Jun 2022 by

The use of biosimilars of infliximab (IFX) and adalimumab (ADA) is both safe and effective in children with inflammatory bowel disease (IBD), inducing high rates of failure-free survival with a low incidence of adverse events, according to a study presented at the 2022 Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN 2022).

Infliximab, adalimumab biosimilars effective, safe in paediatric IBD

27 Jun 2022

Regular statin use offers protection against diabetes in acute pancreatitis patients

27 Jun 2022

Regular statin users appear to be at lower risk of developing diabetes mellitus following an episode of acute pancreatitis, as shown in a study.

Regular statin use offers protection against diabetes in acute pancreatitis patients

27 Jun 2022

Glargine, degludec improve glycaemic control in patients switching from first-gen insulin

27 Jun 2022

Among type 2 diabetes (T2D) patients on first-generation basal insulins (1BIs), a switch to either glargine or degludec in the real-world setting leads to marked improvements in glucose control without increasing the risk of hypoglycaemic events and weight gain, according to a study. Furthermore, the benefits seem to be comparable between the two second-generation basal insulins (2BIs).

Glargine, degludec improve glycaemic control in patients switching from first-gen insulin

27 Jun 2022

Revacept beneficial to patients with symptomatic ICA stenosis

26 Jun 2022

Patients with symptomatic internal carotid artery (ICA) stenosis may fare well with revacept, a competitive antagonist of glycoprotein VI, as the drug helps reduce the incidence of stroke or death, transient ischaemic attack, and bleeding complications, among others, according to a study.

Revacept beneficial to patients with symptomatic ICA stenosis

26 Jun 2022

$Add-on baclofen eases reflux in certain PPI-refractory GERD patients$

Add-on baclofen eases reflux in certain PPI-refractory GERD patients

26 Jun 2022

In patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD), add-on treatment with baclofen improves several reflux parameters, but only among those who are positive for symptom association probability, a study has found.

Add-on baclofen eases reflux in certain PPI-refractory GERD patients

26 Jun 2022

P-gp/CYP3A4 inhibitor use ups bleeding, mortality risks in NOAC-treated AF patients

26 Jun 2022

Bleeding and mortality risks are elevated in atrial fibrillation (AF) patients treated with nonvitamin K antagonist oral anticoagulant (NOAC) who are also using P-glycoprotein (P-gp) and CYP3A4 inhibitors, reports a study, noting the need for close monitoring of these individuals.

P-gp/CYP3A4 inhibitor use ups bleeding, mortality risks in NOAC-treated AF patients

26 Jun 2022

Novel oral neoadjuvant therapy shows promising phase II results

25 Jun 2022

The novel neoadjuvant therapy S-1, an oral fluoropyrimidine agent containing tegafur, gimeracil, and oteracil potassium, yields promising survival outcomes in high-risk patients with resectable pancreatic ductal adenocarcinoma, a recent study has found.

Novel oral neoadjuvant therapy shows promising phase II results

25 Jun 2022

News & Updates

Filter by Specialty:

Specialty:

Stinging, burning sensation after DED medication use a major concern to patients

Stinging, burning sensation after DED medication use a major concern to patients

Vonoprazan superior to PPI for heartburn resolution in erosive esophagitis patients

Vonoprazan superior to PPI for heartburn resolution in erosive esophagitis patients

Pharmacist intervention confers benefits on cardiovascular outcomes

Pharmacist intervention confers benefits on cardiovascular outcomes

Infliximab, adalimumab biosimilars effective, safe in paediatric IBD

Infliximab, adalimumab biosimilars effective, safe in paediatric IBD

Regular statin use offers protection against diabetes in acute pancreatitis patients

Regular statin use offers protection against diabetes in acute pancreatitis patients

Glargine, degludec improve glycaemic control in patients switching from first-gen insulin

Glargine, degludec improve glycaemic control in patients switching from first-gen insulin

Revacept beneficial to patients with symptomatic ICA stenosis

Revacept beneficial to patients with symptomatic ICA stenosis

Add-on baclofen eases reflux in certain PPI-refractory GERD patients

Add-on baclofen eases reflux in certain PPI-refractory GERD patients

P-gp/CYP3A4 inhibitor use ups bleeding, mortality risks in NOAC-treated AF patients

P-gp/CYP3A4 inhibitor use ups bleeding, mortality risks in NOAC-treated AF patients

Novel oral neoadjuvant therapy shows promising phase II results

Novel oral neoadjuvant therapy shows promising phase II results